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Non cell-autonomous processes are thought to play
critical roles in the cellular maintenance of the
healthy and diseased brain but mechanistic details
remain unclear. We report that the interruption of
a non cell-autonomous mode of sonic hedgehog
(Shh) signaling originating from dopaminergic
neurons causes progressive, adult-onset degenera-
tion of dopaminergic, cholinergic, and fast spiking
GABAergic neurons of the mesostriatal circuit,
imbalance of cholinergic and dopaminergic neuro-
transmission, and motor deficits reminiscent of Par-
kinson’s disease. Variable Shh signaling results in
graded inhibition of muscarinic autoreceptor- and
glial cell line-derived neurotrophic factor (GDNF)-
expression in the striatum. Reciprocally, graded
signals that emanate from striatal cholinergic
neurons and engage the canonical GDNF receptor
Ret inhibit Shh expression in dopaminergic neurons.
Thus, we discovered a mechanism for neuronal
subtype specific and reciprocal communication
that is essential for neurochemical and structural
homeostasis in the nigrostriatal circuit. These results
provide integrative insights into non cell-autono-
mous processes likely at play in neurodegenerative
conditions such as Parkinson’s disease.
INTRODUCTION
Neuronal computations in the basal ganglia rely on correlated
changes in the activity of mesencephalic dopamine (DA) neurons306 Neuron 75, 306–319, July 26, 2012 ª2012 Elsevier Inc.and striatal acetylcholine (ACh) and fast-spiking (FS) GABAergic
neurons, which result from reciprocal pre- and postsynaptic
interactions (Threlfell et al., 2010). The concerted activity of DA
neurons and ACh and FS interneurons gate glutamatergic input
from the cerebral cortex and thalamus onto medium spiny pro-
jection neurons (MSN) allowing the translation of thought into
action (Figure 1) (Bolam et al., 2006). These neuronal subtypes
form cartridges of a repetitive mesostriatal circuit in which
each of the numerous MSN contributes to only few units, but
each of the many fewer DA, ACh, and FS neuron participates in
several 100 units (Bolam et al., 2006). The phylogenetic conser-
vation of circuit architecture (Reiner, 2010) suggests that the rela-
tive proportions of the constituent neurons of the mesostriatal
circuit are important for proper circuit function. This view is sup-
ported by the pathophysiological finding that chorea, parkin-
sonism, and tics are associated with a loss of specificmesostria-
tal constituent neuronal subtypes such as MSN, DA, and FS
neurons, respectively (DeLong and Wichmann, 2009).
The mechanisms maintaining cellular and neurochemical
homeostasis in the mature mesostriatal system in the healthy
brain are not fully elucidated, but signaling by neurotrophic
factors has emerged as a likely process. For example, the glial
cell line-derived neurotrophic factor (GDNF) protects catechol-
aminergic neurons from toxic insults, induces fiber outgrowth
and is required for catecholaminergic neuron survival in the adult
brain (Lin et al., 1993; Pascual et al., 2008). GDNF signaling can
also act as a neuromodulator of dopaminergic signaling through
the regulation of the quantal size of DA release (Pothos et al.,
1998; Wang et al., 2001). Despite the implication of GDNF in
DA neuron maintenance and function, which motivated several
clinical trials of GDNF-based therapies in Parkinson’s disease
(PD) (Rangasamy et al., 2010), the regulation of GDNF expres-
sion in the healthy adult brain remains ill-defined.
Circumstantial evidence also implicates the secreted glyco-
protein Sonic Hedgehog (Shh) in the maintenance of the
Figure 1. Mesostriatal Circuitry
Striatal interneurons andMSNs receive dopaminergic projections. ACh and FS
interneurons project to striatal neuronal subtypes and dopaminergic projec-
tions. ACh, acetylcholine; Cal, calretinin; ChAT, choline-acetyl transferase; DA,
dopamine; FS, ‘‘fast spiking’’; GABA, g-aminobutyric acid; Glut, glutamine;
MSN; medium spiny projection neurons; Parv, parvalbumin; Som, somato-
statin; Th, tyrosine hydroxylase; vMB, ventral midbrain.
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Shh Signaling in the Mesostriatal Circuitmesostriatal circuit because exogenously supplied Shh to the
adult striatum increases the resilience of mesencephalic DA
neurons to MPTP and 6-OHDA, neurotoxins used to model
PD-related DA neuron loss in animals (Dass et al., 2005; Tsuboi
and Shults, 2002). In these paradigms, the neuroprotective effect
of Shh on mesencephalic DA neurons is comparable to that
observed with striatal delivery of GDNF (Dass et al., 2002).
In vitro, Shh synergizes with neural growth factor (NGF) in
providing trophic support to basal forebrain-derived, postnatal
ACh neurons (Reilly et al., 2002). Despite these observations, it
is not clear whether there is a functionally relevant source of
Shh that could act in the mature mesostriatal system and if so,
which cell types would communicate by Shh signaling.
Here, we present evidence for reciprocal, trophic factor
signaling between mesencephalic DA, striatal ACh, and FS
neurons. We show that DA neurons utilize Shh to signal to ACh
and FS interneurons in the striatum where it regulates extracel-
lular ACh tone, expression of GDNF, and maintenance of these
neurons. Conversely, Shh expression by DA neurons is re-
pressed by signals that originate from ACh neurons and engage
the canonical GDNF receptor Ret on DA neurons. The condi-
tional ablation of Shh from DA neurons results in a progressive
model of PD with face, construct and predictive validity. Thus,
our results shed light onto aspects of the chemical neuro-
anatomy of the basal ganglia andmay have far-reaching implica-
tions for the understanding of the physiopathology and the treat-
ment of movement disorders such as PD.
RESULTS
Shh Expression by DA Neurons Is Necessary for the
Long-Term Maintenance of Mesencephalic DA Neurons
To examine whether Shh-mediated signaling occurs among
neurons of the mesostriatal circuit, we first visualized expression
of Shh in the adult brain using mice heterozygous for a condi-
tional, gene expression tracer allele of Shh (Shh-nLZC/+) (Fig-
ure S1A available online). We observed Shh expression by all
tyrosine hydroxylase-positive (Th+) neurons in the substantia
nigra pars compacta (SNpc) (Figures 2A and 2B), the ventral
tegmental area (VTA) (Figure 2A), and the retrorubral field (RRF,
data not shown) along the entire rostro-caudal axis of these
nuclei at 3 months of age (100 ± 0%, 683 cells, n = 2). We did
not observe Shh expression by Th+ neurons of the diencephalon
or olfactory bulb or by cells in the striatum (data not shown).
To determine whether Shh signaling within the mesostriatal
circuit is of physiological relevance, we selectively ablated Shh
expression from DA neurons mediated by Cre activity expressed
from the DA transporter locus (Dat-Cre; all mouse strains used in
this study are referenced in Supplemental Experimental Proce-
dures). Shh-nLZC/C/Dat-Cre mutant animals were born alive
and mobile with expected Mendelian frequency and no overt
structural or motor signs at the end of postnatal development
compared to Shh-nLZC/+/Dat-Cre control littermates (Figures
S1 and S2; Table S1; Supplemental Results A and B; for all
comparative analyses herein littermates double heterozygous
for Shh-nLZC/+and Dat-Cre served as controls).
Unbiased stereological cell counting of Th+ and Th neurons in
the SNpc and VTA revealed an adult-onset, progressive degen-eration of DA neurons that plateaus at 40% in Shh-nLZC/C/
Dat-Cre mice compared to controls at 8 months of age (Figures
2C–2F and 2I). No change in the number of glutamate decarbox-
ylase (GAD67)-positive cells was observed in the SN pars
reticulata of Shh-nLZC/C/Dat-Cremice at 16 months of age (Fig-
ure S3A). Striatal Th+-fiber density was normal at 1month of age,
increased at 8 months and decreased at 12 months of age in
Shh-nLZC/C/Dat-Cre mice compared to controls (Figure 2F).
Gene expression analysis of DA markers in the ventral midbrain
(vMB) revealed a downregulation of Th, Dat, and DA receptor-2
(DaR2) at 5 weeks of age, which then returned to normal levels
by 12 months in Shh-nLZC/C/Dat-Cre compared to controls
(Figure 2G; all genes probed herein are listed in Table S2). The
expression of the vesicular monoamine transporter-2 (vMat2)
appeared normal at 5 weeks, but was diminished at 12 months.
The activator of endoplasmic reticulum stress, Xbp1, and the
antioxidant enzyme, glutathione-peroxidase-1 (Gpx1), were
upregulated in Shh-nLZC/C/Dat-Cre animals at 5 weeks but not
at 12 months of age (Figure 2G) indicative of the activation of
physiological cell stress responses in the vMB in the absence
of Shh expression in young adult mutant mice. In further support
of a protracted dopaminergic cell syndrome in which neuronal
degeneration is only the final step, we found progressive alter-
ations in somato-dendritic and striatal DA content and deficits
in amphetamine elicited DA release in Shh-nLZC/C/Dat-Cre
mice (Supplemental Results C and Figures S3B–S3D).
Is the observed dopaminergic phenotype a cell autonomous
effect of the interruption of Shh signaling? Shh can bind to
several coreceptors which in turn facilitate the relief of repression
of the serpentine transmembrane protein Smo by Ptc1 or Ptc2
(Izzi et al., 2011). To distinguish autocrine from paracrine Shh
signaling, we analyzed the expression of the Shh coreceptors
Ptc1 and Ptc2 and the phenotype of animals with a tissueNeuron 75, 306–319, July 26, 2012 ª2012 Elsevier Inc. 307
Figure 2. Ablation of Shh from DA Neurons
Results in Non Cell-Autonomous DA Neuron
Degeneration
(A) X-Gal labeled coronal section of the vMB of
a Shh-nLZc/+ mouse.
(B) 100 ± 0% of Th+ dopaminergic neurons in the
mesencephalon express Shh at p90 (for all quan-
titations herein, data are represented as mean ±
SEM; 683 cells, 2 mice).
(C) Th staining of VTA and SNpc is inconspicuous
at one month but diminished at 12months of age in
Shh-nLZC/C/Dat-Cre mice.
(D) Progressive reduction in the numbers of Th+
neurons in the SNpc in Shh-nLZC/C/Dat-Cre mice.
(*p < 0.05, unpaired t test; n = 7-8/genotype/age,
12 sections per subject with a 5-section interval;
mean ± SEM).
(E) Progressive reduction in the numbers of Th+
neurons in the VTA in Shh-nLZC/C/Dat-Cre mice.
(*p < 0.05, unpaired t test; n = 5/genotype/age, 12
sections per subject with a 5-section interval;
mean ± SEM).
(F) Striatal Th+ nerve fiber density in Shh-nLZC/C/
Dat-Cre mice (*p < 0.05 unpaired t test, n = 10-11/
group; mean ± SEM).
(G) Alterations in gene expression in the vMB of
4-week- and 12-month-old Shh-nLZC/C/Dat-Cre
mice. (For all quantitative gene expression analysis
herein data is expressed as relative fold change of
experimental over control conditions with down-
regulation shown as red bars and upregulation
shown as green bars. *p < 0.01, **p < 0.001 two-
tailed t test; n = 5/genotype; mean ± SEM).
(H) Th staining of VTA and SNpc is inconspicuous
at 18 months of age in SmoC/C/Dat-Cre mice.
(I) Comparative quantification of DA and non-DA
neurons in the SNpc and VTA of 12- and 18-month-
old Shh-nLZC/C/Dat-Cre and SmoC/C/Dat-Cre
mice, respectively (*p < 0.05 unpaired t test;
n = 6–7/group; mean ± SEM).
See also Figures S1, S2, and S3 and Table S2.
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Shh Signaling in the Mesostriatal Circuitrestricted ablation of Smo from DA neurons, which we produced
using the same Dat-Cre allele with which we also achieved the
tissue specific ablation of Shh. We did not find evidence for the
expression of Ptc1 in DA neurons utilizing a gene expression
tracer mouse line (Ptc1-nLZ) or Ptc2 by in situ hybridization,
consistent with public gene expression data information (Gen-
sat, http://www.gensat.org; data not shown). SmoC/C/Dat-Cre
mutant animals were born alive and mobile with expected
Mendelian frequency and no overt structural or motor signs
through adulthood compared to SmoC/+/Dat-Cre control litter-
mates (data not shown). Unbiased stereological cell counting
of Th+ and Th neurons in the SNpc and VTA of 18-month-old
SmoC/C/Dat-Cre mutants and SmoC/+/Dat-Cre littermate
controls did not reveal DA neuron loss in the SNpc or VTA308 Neuron 75, 306–319, July 26, 2012 ª2012 Elsevier Inc.(Figures 2H and 2I). Collectively, the anal-
yses of the vMB demonstrates a progres-
sive structural and functional deterioration
of the mesencephalic DA system in the
absence of DA neuron produced Shh,whose cardinal cellular and functional aspects results from
a non cell-autonomous mode of Shh signaling.
DA Neuron-Expressed Shh Acts as a DA Neuron
Protectant
Dat-Cre-mediated ablation of the conditional Shh allele is80%
complete in the SNpc at 2 months of age creating an experimen-
tally induced heterogeneity among DA neurons in regard of Shh
expression (Figure S2A). We therefore explored whether the
progressive nature of the phenotype might be caused by slowly
continuous Cre-mediated deletion of Shh alleles over time in
adult Shh-nLZC/C/Dat-Cre mutant animals. In contrast to this
prediction, however, we observed an increase in the relative
numbers of Shh expressing DA neurons among all DA neurons
Figure 3. Shh Expression Confers a Survival Advantage to Dopami-
nergic Neurons
(A) Shh expressing DA neurons in Shh-nLZC/C; Dat-Cre mice at 12 months
of age.
(B) Incidence of Shh expression in the SNpc in Shh-nLZC/C; Dat-Cre mice at
1 and 12 months of age (*p < 0.05, unpaired t test, n = 12/group, 100 cells/
subject; mean ± SEM).
(C) Somatic area of Th+, Shh and Th+, Shh+ cells in the SNpc of Shh-nLZC/C;
Dat-Cre mice (*p < 0.05, single comparison by Mann-Whitney U test; box-
whisker plots for median ± 95% confidence interval [CI] bar, 25–75 percentiles
box, n = 4, 20 cells/subject).
See also Figure S1 and S2.
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Shh Signaling in the Mesostriatal Circuitof the SNpc from 20% at 2 months of age to 37% at
12 months of age in Shh-nLZC/C/Dat-Cre mutants (Figures 3A
and 3B). We also observed that the soma size of Shh expressing
DA neurons was larger than of DA neurons that lost Shh expres-
sion inShh-nLZC/C/Dat-Cremice at 12months of age (Figure 3C).
These observations demonstrate that (1) accumulation of Shh
null alleles by continuousCre activity is insignificant after 8weeks
of age, and (2) Shh-expressing DA neurons have a selective
survival advantage over DA neurons in which Cre-mediated
Shh ablation occurred. Thus, these results provide genetic
evidence that Shh signaling originating specifically from DA
neurons confers a competitive survival advantage among
mesencephalic DA neurons in vivo.
Dopamine Substitution and Cholinergic Antagonist
Treatment Normalize Progressive Gait and Locomotion
Disturbances in Shh-nLZC/C/Dat-Cre Mice
Next, we assessed the functional significance of the progressive
structural and neurochemical alterations of the mesencephalic
DA system in Shh-nLZC/C/Dat-Cremice by longitudinal analyses
of elicited and spontaneous motor performance.
Analysis of horizontal activity profiles of freely locomotingmice
in an open field let us define successive phases of progressive
changes in locomotion of Shh-nLZC/C/Dat-Cre mice compared
to control litter mates: locomotion activity was normal up to
6 weeks (phase I), reduced by 35% at 2–5 months (phase II),
increased by 60% at 7–12 months (phase III), inconspicuous
at 16 months (phase IV), but then rapidly deteriorating leading
first to pelvic dragging, followed by partial hind limb paralysis
and premature death at about 18 months (phase V; Figure 4A).
The switch from relative hypoactivity to relative hyperactivity of
Shh-nLZC/C/Dat-Cremice compared to control littermates man-
ifested with high temporal specificity around 6 months of age
(Figure 4B). The inversion in relative locomotion activity coin-
cided with a switch from a 3-fold reduction to a 30% increase
in striatal DA content (Figure S3C and Supplemental Results C)
and a relative increase in the frequency of bouts of locomotion
from phase II to phase III in Shh-nLZC/C/Dat-Cremice compared
to controls (data not shown).
We next investigated gait dynamics by ventral plane videog-
raphy of Shh-nLZC/C/Dat-Cremice and controls of 3–16 months
of age walking on a translucent treadmill. During phase III, the
gait length coefficient of variability was increased 30% at
10 months of age, and the time allotted for braking in each stride
was shortened by 40% and the paw angle was increased by
50% at 11 months of age of Shh-nLZC/C/Dat-Cre mice relative
to controls (Figure 4C and Supplemental Results D; see Table
S1for all indices of gait analyzed). We then tested whether drugs
efficacious in the management of PD would modify the locomo-
tion abnormalities of Shh-nLZC/C/Dat-Cremice. We systemically
injected L-DOPA (dopamine precursor) trihexylphenidate (THP)
(muscarinic antagonist), or vehicle 30 min prior to the analysis
of locomotion in 12-month-old Shh-nLZC/C/Dat-Cre and control
mice. The increased variability in stride length was normalized by
L-DOPA and THP, brake stride ratios were normalized by THP
but not L-DOPA, and alterations in paw angles were normalized
by L-DOPA, but not THP (Figure 4D). Taken together,
our behavioral studies revealed a dynamic and progressive loco-motion phenotype whose pharmacological responsiveness
suggests underlying alterations in the functional balance of
dopaminergic and cholinergic neurotransmission.
Ablation of Shh from DA Neurons Results in Progressive
Cellular and Functional Corruption of the Adult Striatum
Similarly to BDNF, which supports survival of cortical-striatal
neurons (Baquet et al., 2004), Shh can also be transported ante-
rogradely through axons (The´rond, 2012). Because of the lack of
evidence for an autocrine mechanism for Shh dependent
support of DA neurons we therefore hypothesized that Shh
signaling from dopaminergic projections to striatal targets might
be of relevance to the maintenance of DA neurons.
We found that 25% of all Ptc1+ cells in the striatum are
neurons (Figures 5A–5C) and that 6%of all striatal neurons coex-
press Ptc1 (Figure 5F). Conversely, 100% of all ACh neurons and
98%of all FS interneurons express Ptc1 (Figures 5D–5F), consis-
tent with the relative prevalence of ACh and FS neurons among
all striatal neuronal subtypes (Bolam et al., 2006). Hence, ourNeuron 75, 306–319, July 26, 2012 ª2012 Elsevier Inc. 309
Figure 4. Abnormalities in Locomotion and
Gait Dynamics in the Absence of Shh
Expression by DA Neurons
(A) Horizontal activity in an ‘‘Open Field’’ as
a function of age (*p < 0.05, repeated-measures
ANOVA follow by Tukey’s post hoc test; n = 10/
group; mean ± SEM).
(B) High temporal predictability of transition from
phase II to phase III (n = 83–100; 23 litters;
p < 0.000001, phase 3 genotype ANOVA;
mean ± SEM).
(C) Increase in coefficient of stride length variability
(CV), reduction in brake/stride ratio, and increase
in absolute paw angle during phase III in Shh-
nLZC/C/Dat-Cre (n = 5; p < 0.01; ANOVA followed
by Tukey’s test; mean ± SEM).
(D) Normalization of stride length CV, braking time
and paw angle by L-DOPA (subcutaneously,
20 mg/kg) and/or THP (subcutaneously, 3 mg/kg;
n = 8/genotype; *p < 0.05, genotype 3 time
ANOVA for repeated measures followed by
Tukey’s post hoc test; mean ± SEM).
See also Table S1.
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Shh Signaling in the Mesostriatal Circuitexpression data suggested that mesencephalic DA neurons
could communicate by Shh signaling selectively with all ACh
and FS neurons, and nonneuronal cells among their projection
targets in the adult striatum.
InShh-nLZC/C/Dat-Cremice compared to controls at 6months
of age, we observed a reduction in the number of ChAT+ neurons
in the striatum that was most pronounced in lateral/anterior
aspects of the dorsal striatum (Figures 5G and S4A–S4C). ACh
and FS interneurons make up together only 6% of total striatal
neurons (Figure 5F) and are locally projecting. These attributes
make it impossible to distinguish neuronal loss from downregu-
lation of phenotypic marker expression by the quantitation of the
total number of neurons or the exploitation of specific projection
patterns. However, themain striatal cell populations can be iden-
tified based on cell type specific perinuclear staining patterns
that can be visualized by the DNA intercalating dye ToPro3
(Figures S5A–S5C). Based on this technique, we found a
40% reduction in the numbers of ACh and FS interneurons
but no change in the numbers of calretinin and somatostatin
interneurons, MSN, and nonneuronal cells in 4-month-old Shh-
nLZC/C/Dat-Cre mice compared to controls (Figure 5H). ACh310 Neuron 75, 306–319, July 26, 2012 ª2012 Elsevier Inc.and FS neurons as a group exhibit the
largest nuclei and can therefore be distin-
guished from all other striatal cells by a
nuclear circumference larger than 28 mm
(Figure S5C). This second approach, re-
vealed a 60% reduction of the numbers
of striatal cells with nuclear circumfer-
ence larger than 28 mm in 12-month-old
Shh-nLZC/C/Dat-Cre mice compared to
controls (Figure 5H). Stereological quanti-
tation of ACh and FS neurons using ChAT
and parvalbumin immunohistochemistry
revealed an adult-onset, progressive
reduction in the numbers of ChAT+ andparvalbumin+ cells, which plateaus at 8 months of age at
50% and 40%, respectively (Figures 5I and 5K). The kinetics
of striatal ACh andmesencephalic DA neuron degeneration were
correlated (R2 = 0.98; p < 0.006; Figures 5I and 2D). Consistent
with the activation of physiological cell stress response path-
ways in ACh and FS neurons prior to neurodegeneration,
we found increased expression of the luminal endoplasmic
reticulum (ER) protein BiP/Grp78 by large bodied cells in the
striatum by mRNA in situ hybridization at 5 weeks of age which
then becomes more pronounced at 12 months of age (Figures
S6A–S6D). Thus, in aggregate, the analyses of perinuclear stain-
ing pattern, nuclear size, and cell type specific marker gene
expression, demonstrate a cell type selective, adult-onset,
progressive degeneration of ACh and FS neurons in the
striatum in the absence of Shh expression by mesencephalic
DA neurons that is correlated with the degeneration of DA
neurons themselves.
We next examined steady state, extracellular ACh levels in
the striatum by in vivo dialysis. Despite a mere 50% loss of
ACh neurons, we found a 6-fold, reduction in basal levels of
extracellular ACh in 8-month-old Shh-nLZC/C/Dat-Cre mice
Neuron
Shh Signaling in the Mesostriatal Circuitcompared to controls (Figure 5L). This observation suggests that
surviving ACh neurons cannot functionally compensate for the
reduction in their numbers in absence of Shh signaling from DA
neurons.
To explore the molecular underpinnings of the inability of
surviving ACh neurons to increase ACh production, we investi-
gated the expression levels of candidate genes, which could
inform about the neurophysiological status of the striatum
before (at 5 weeks of age) and after (at 12 months of age) the
onset of neurodegeneration. We found that the expression of
striatal ChAT, vesicular acetylcholine transporter (vAChT),
and GTPase regulator RGS4 were downregulated whereas the
expression of striatal muscarinic autoreceptor M2 was upregu-
lated in 5-week-old Shh-nLZC/C/Dat-Cre mice compared to
controls (Figure 5M(1)). The expression of ChAT, M2, and
RGS4 was further distorted at 12 months of age whereas the
expression of vAChT returned to normal levels (Figure 5M(1)).
Acetylcholine esterase (AChE) expression was unaltered at
5 weeks but reduced at 12 months of age consistent with
the observed reduction of striatal ACh levels in older animals
(Figure 5M(1)). ACh tone in the striatum is in part regulated
by muscarinic autoreceptors M2 and M4 whose functions in
turn are negatively modulated by the GTPase accelerator
RGS4 (Ding et al., 2006). Thus, the observed upregulation of
M2 and downregulation of RGS4 gene expression indicate an
enhancement of cholinergic autoreceptor function in surviving
ACh neurons in the striatum of Shh-nLZC/C/Dat-Cre mice
consistent with the observed reduction in striatal cholinergic
tone.
In contrast to the situation in ACh neurons, parvalbumin gene
expression was strongly reduced at 5 weeks of age, but reached
normal levels at 12 months suggesting a compensatory upregu-
lation by surviving FS neurons (Figure 5M(2)). General
GABAergic marker and DA receptor gene expression were not
affected at 5 weeks but DA receptors D1–D4, DARP32, and
Gad1were downregulated, while DA receptor interacting protein
(D-IP) was upregulated at 12 months of age (Figure 5M(2)) sug-
gesting that GABAergic neuronal subtypes in addition to FS
neurons in the striatum become phenotypically involved subse-
quently to ACh and FS neurons.
In support of a direct control of gene expression by Shh
signaling in the striatum, we found that the transcription
factor Gli3, whose expression is inhibited by Shh signaling (Ulloa
and Briscoe, 2007), is upregulated by the Smo antagonist
cyclopamine (Chen et al., 2002) and downregulated by the
Smo agonist ‘‘SAG’’ (Frank-Kamenetsky et al., 2002) when
injected into the adult striatum of C57Bl/6 wt mice (Figure 5M(3)).
M2 expression was also acutely and dose-dependently in-
creased by cyclopamine and decreased by SAG injection into
the striatum, indicating that Shh signaling impinges directly
on the regulation of cholinergic tone in the healthy striatum
(Figure 5M(3)).
Thus, the absence of Shh signaling originating from DA
neurons elicits a sequential structural and functional corruption
of the striatum which begins with cell physiological alterations
in ACh and FS neurons and culminates in a progressive, adult-
onset degeneration of ACh and FS neurons without compensa-
tory adaptations of surviving ACh neurons.DA Neuron-Derived Shh Maintains the Cellular Source
of GDNF but Represses Its Transcription in the Striatum
GDNF is expressed by ACh and FS interneurons (Hidalgo-
Figueroa et al., 2012). Consistent with the Shh-dependent main-
tenance of ACh and FS neurons, we found a progressive reduc-
tion in GDNFmRNA and protein expression, and an upregulation
of the canonical receptor Ret and its coreceptor Gfra1, which
bind all members of the GDNF family of ligands, in the striatum
of Shh-nLZC/C/Dat-Cre mice compared to controls (Figures 6A
and 6B). The progressive reduction in striatal GDNF tissue
content correlated with the progressive degeneration of ACh
neurons in Shh-nLZC/C/Dat-Cre mice (Figures 6B and 2D;
R2 = 0.95, p < 0.02 for ACh neurons). We then utilized the chol-
inotoxin AF64a, which causes reversible inhibition of ACh
neurons at moderate concentrations and ACh neuron degenera-
tion at higher concentration (Sandberg et al., 1984) to assess the
relative contribution of ACh neurons over other sources to GDNF
production in the striatum. We found that unilateral striatal injec-
tions ofmoderate concentrations of AF64a led to a30% reduc-
tion in striatal GDNF protein content over vehicle injected
controls 36 hr after toxin application in 4-month-old C57Bl/6 wt
animals (Figure 6C). Together, these experiments demonstrate
that Shh signaling originating from mesencephalic DA neurons
contribute to the long-term maintenance of striatal GDNF
production through trophic support of striatal ACh and FS
neurons.
The analysis of the long-term effects of the chronic absence of
Shh signaling from DA neurons does not provide information
about whether Shh signaling plays a role in the transcriptional
regulation of striatal GDNF expression in the absence of physio-
logical cell stress and/or neurodegeneration. We therefore
examined whether Shh signaling regulates striatal GDNF gene
expression acutely by unilaterally injecting SAG or cyclopamine
in 8-week-old C57/Bl6 male mice (Figure 6D). Comparative qRT-
PCR analysis revealed a SAG specific reduction in GDNF mRNA
and a dose-dependent, cyclopamine specific increase in GDNF
mRNA 30 hr after injection (Figures 6E and 6F), demonstrating
that GDNF expression in the adult striatum is dynamically regu-
lated by Shh signaling. Consistent with the inhibition of GDNF
expression by Shh signaling originating from DA neurons we
observed an upregulation of GDNF in the striatum upon the inter-
ruption of the mesostriatal pathway by the unilateral injection of
6-OHDA into the medial forebrain bundle (mFB) of GDNF-LZ
mice (Figure 6F). Together with the finding that systemic injec-
tions of the dopaminergic toxin MPTP results in the transient
upregulation of striatal GDNF expression (Hidalgo-Figueroa
et al., 2012), our results suggest that the relevant Shh signal
for the regulation of GDNF expression in vivo could come from
the vMB.
Guided by these results, we tested whether Shh produced
specifically by DA neurons acutely regulates the expression of
GDNF in the mesostriatal system in vivo. The pedunculopontine
tegmental nucleus (PPTg) provides excitatory, nicotinic receptor
mediated cholinergic input to mesencephalic DA neurons
(Futami et al., 1995) (Figure 6G). Similar to previous observations
upon the excitotoxic ablation of PPTg neurons (Dunbar et al.,
1992), we found that unilateral injection of the cholinotoxin
AF64a into the PPTg of 2-month-old Shh-nLZC/C/Dat-Cre- orNeuron 75, 306–319, July 26, 2012 ª2012 Elsevier Inc. 311
Figure 5. Neuronal Subtype Specific and Progressive Degeneration in the Striatum in Absence of Shh Signaling from Mesencephalic DA
Neurons
(A) X-Gal labeled coronal section of striatum of a Ptc1-nLZ mouse.
(B) Ptc1 expression in neuronal and nonneuronal cells of the striatum.
(C) Twenty-five ± 5.2% of Ptc1+ striatal cells are neurons (n = 612 cells, 3 mice).
(D) Ptc1 expression in striatal ACh neurons.
(E) Ptc1 expression in striatal FS neurons.
(F) Six ± 2.2% of striatal neurons express Ptc1 (n = 420 cells, 3 mice); 100 ± 0% of ACh neuron express Ptc1 (n = 140 cells, 3 mice); 98 ± 2.0% of FS neurons
express Ptc1 (n = 150 cells, 3 mice).
(G) Loss of Ach neurons is most pronounced in lateral areas of the dorsal striatum (circled in red; quantitation in Figure S4) in Shh-nLZC/C/Dat-Cre mice.
(H) Quantification of striatal cell types by heterochromatin pattern (Figures S6A and S6B) and nuclear size (Figure S6C) in Shh-nLZC/C/Dat-Cre. (*p < 0.05,
**p < 0.001, t test (10 striatal slices/subject, n = 7 mice per genotype; mean ± SEM).
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Figure 6. Shh Signaling Inhibits GDNF Expression in the Striatum
(A) Changes in GDNF, Ret, andGfra1 gene expression in the striatum of 4-week-old and 12-month-oldShh-nLZC/C/Dat-Cremice (*p < 0.01, **p < 0.001, two tailed
t test; n = 5/genotype; mean ± SEM).
(B) Quantification of striatal GDNF tissue content as a function of age in Shh-nLZC/C/Dat-Cre mice (*p < 0.01, unpaired t test; n = 10–11/group; mean ± SEM).
(C) Injection of AF64a reduces GDNF tissue content. (37 ± 3%; *p < 0.05, unpaired t test; n = 12–14/group; mean ± SEM).
(D) Experimental design: comparative analysis of GDNF expression upon unilateral injection of SAG or cyclopamine into the striatum ofwtmice, or 6-OHDA into
the mFB of GDNF-LZ+/ mice.
(E) SAG decreases GDNF mRNA expression (*p < 0.05, ANOVA followed by Tukey’s post hoc Test; n = 5/group/drug concentration; mean ± SEM).
(F) Injection of cyclopamine into the striatum or 6-OHDA into the mFB increases GDNF mRNA expression (*p < 0.05, ANOVA followed by Tukey’s post hoc test;
n = 5/group/drug concentration; the upregulation caused by cyclopamine was dose-dependent; mean ± SEM).
(G) Experimental design: comparative analysis of gene expression in the vMB and striatum upon unilateral injection of AF64a into the PPTg.
(H) Quantification of turning bias 36 hr postunilateral injection of AF64a into the PPTg in Shh-nLZC/C/Dat-Cre mice (*p < 0.05, post hoc test after ANOVA;
n = 5/genotype; mean ± SEM).
(I and K) Quantification of changes in gene expression in the vMB (I) or striatum (K) upon AF64a injection into the PPTg of Shh-nLZC/C/Dat-Cre and control mice
(**p < 0.001, AF64a x genotype ANOVA followed by Tukey’s post hoc test; n = 5/group/genotype; mean ± SEM).
See also Figures S1 and Table S2.
Neuron
Shh Signaling in the Mesostriatal Circuitcontrol mice elicited a contralateral turning bias consistent with
reduced cholinergic stimulation of ipsilateral DA neurons (Fig-
ure 6H) (Lester et al., 2010). Comparative qRT-PCR analysis of
dopaminergic markers between the ipsilateral and contralateral
vMB revealed a transcriptional upregulation of Th and a downre-
gulation of the DA autoreceptor DaR2 ipsilateral in both geno-
types, suggesting an adaptive upregulation of mesencephalic(I) Progressive reduction in the numbers of ChAT+ neurons in the striatum in Shh-
subject with a 5-section interval; mean ± SEM).
(K) Progressive reduction in the numbers of Parv+ FS neurons in the striatum in Sh
subject with a 5-section interval; mean ± SEM).
(L) Reduced extracellular ACh concentration in the striatum in 8 month old Shh-n
subject; mean ± SEM).
(M) Quantification of changes in gene expression in the striatum of 4-week-old and
of increasing concentrations of SAG or cyclopamine (*p < 0.01, **p < 0.001, two
See also Figure S5 and Table S2.DA signaling upon AF64a injection into the PPTg (Figure 6I).
AF64a injection into the PPTg also resulted in a10-fold upregu-
lation of Shh transcription in the ipsilateral vMB compared to the
contralateral control (Figure 6I). Thus, the comparative analysis
of Shh-nLZC/C/Dat-Cre mice, which are unable to express
functional Shh, and of Shh-nLZC/+/Dat-Cre control animals
allows the distinction of Shh dependent and independentnLZC/C/Dat-Cremice (p < 0.05, unpaired t test; n = 6–7/group, 12 sections per
h-nLZC/C/Dat-Cremice. (*p < 0.05, unpaired t test; n = 4/group, 12 sections per
LZC/C/Dat-Cre mice (**p < 0.001, unpaired t test; n = 8/genotype, 4 samples/
12-month-old Shh-nLZC/C/Dat-Cremice (1 and 2) and after unilateral injection
tailed t test; n = 5/genotype or treatment; mean ± SEM).
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Figure 7. Shh Expression by Mesencephalic DA Neurons Is Repressed by Signals Emanating from ACh Neurons
(A) Experimental design: unilateral injection of AF64a into the striatum or 6-OHDA in the mFB results in ipsi-lateral or contro-lateral, respectively, turning.
(B) Quantification of turning bias upon injection of 6-OHDA into the mFB of wt or GDNF-LZ+/ mice (*p < 0.01, AF64a dose versus vehicle, ANOVA followed by
Tukey’s post hoc test; n = 5/dose; mean ± SEM).
(C) Upregulation of Shh gene expression in the vMB bias upon injection of 6-OHDA into the mFB of wt or GDNF-LZ+/ mice, or AF64a into wt mice (*p < 0.05,
ANOVA followed by Tukey’s post hoc test; n = 5/condition; mean ± SEM).
(D) Quantification of turning bias upon injection of AF64a into wt mice (*p < 0.01, AF64a dose versus vehicle, ANOVA followed by Tukey’s post hoc test; n = 5/
dose; mean ± SEM).
(E) Dose dependent upregulation of Shh gene expression in the vMB bias upon injection AF64a intowtmice (*p < 0.05, ANOVA followed by Tukey’s post hoc test;
n = 5/condition; mean ± SEM).
(F) Shh expression in the vMB is activated in Shh-nLZC/C/Dat-Cre and RetC/C/Dat-Cre mice (50: Shh exon 1 amplimer, 30: Shh exon 2,3 amplimer; n = 4–6/
genotype and age, *p < 0.01; mean ± SEM).
See also Figure S1 and Table S2.
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Shh Signaling in the Mesostriatal Circuitregulation of gene expression in the experimentally undisturbed
striatum that occurs in response to AF64a injection into
the PPTg.
Utilizing this experimental paradigm, we found that the
expression of ChAT and vAChT in the ipsilateral striatum were
downregulated to a similar extent, regardless of Shh expression
by DA neurons compared to the contralateral striatum (Fig-
ure 6K). In contrast, we observed a 4-fold downregulation of
GDNF expression upon AF64a injection into PPTg of control
mice, i.e., mice that produce Shh in DA neurons, but not of
Shh-nLZC/C/Dat-Cre mutant animals (Figure 6K). These results
provide genetic evidence that increased Shh signaling specifi-
cally originating from mesencephalic DA neurons results in the
repression of GDNF transcription in the striatum.
Cholinergic Neurons of the Striatum Regulate Shh
Expression in Mesencephalic DA neurons
The observed upregulation of Shh expression by DA neurons
upon neurotoxic insult to the PPTg suggested that expression
of Shh by DA neurons is not static but could be regulated by
cell extrinsic signals. We therefore explored the dynamic range
of Shh expression and whether the striatum in addition to the314 Neuron 75, 306–319, July 26, 2012 ª2012 Elsevier Inc.PPTg might be a source of signals that could contribute to the
regulation of Shh expression by DA neurons.
We first investigated whether the acute interruption of meso-
striatal communication by unilateral injection of 6-OHDA into
the mFB of C57BL/6 wt and GDNF-LZ-mice alters Shh expres-
sion by DA neurons. Thirty hours after toxin injection, we
observed contralateral turning biases in wt and GDNF-LZ
animals consistent with reduced DA signaling to the striatum
(Figures 7A and 7B). In these animals, we found an upregulation
of Shh expression in the vMB ipsilateral to the toxin injection.
These results suggested that the striatum could be a source of
signals that inhibit Shh expression in the vMB (Figure 7C).
Use of the cholinotoxin AF64a afforded us to test next whether
signals emanating from striatal ACh neurons could contribute to
the repression of Shh transcription in DA neurons. Thirty hours
postunilateral striatal injection of AF64a into wt C57B/6 mice,
we observed a dose-dependent ipsilateral turning bias consis-
tent with a graded increase in striatal motor output due to
a progressive, AF64a induced, inhibition of cholinergic activity
(Figures 7A and 7D) (Lester et al., 2010). In the ipsilateral vMB
of these animals, we found an AF64a dose-dependent, step-
wise, upregulation of Shh transcription correlated with the
Neuron
Shh Signaling in the Mesostriatal Circuitgraded turning bias (R2 = 0.79, p < 0.001; Figure 7E). The upre-
gulation of Shh expression was transient and returned to control
levels by 6 days posttoxin injection (Figure 7E). In addition to Shh
expression, we also found AF64a dose-dependent alterations in
the expression of dopaminergic markers that resembled the
distortions seen in Shh-nLZC/C/Dat-Cre mice (Supplemental
Results D and Figure S3E) indicating that altered signaling by
cholinergic neurons contributes to the dopaminergic cell
syndrome that we observe in the absence of Shh signaling
from DA neurons (Figure 2).
These findings suggested that the transcription of Shh in DA
neurons is activated in Shh-nLZC/C/Dat-Cre mice. Because the
design of the Shh-nLZC/C allele leaves intact the promoter and
most transcriptional enhancer regions of the native Shh locus
after Cre mediated recombination we devised a qPCR based
assay to test whether Shh expression was activated in DA
neurons before and after ACh neuron degeneration in Shh-
nLZC/C/Dat-Cre mice (for technical details see Supplemental
Results A and Figure S1). We found an 5-fold and 4-fold
increase in the transcription of the 50-end of the Shh mRNA
that can be expressed from the truncated Shh locus in Shh-
nLZC/C/Dat-Cre at 4 weeks and 12 months of age, respectively.
Thus, Shh-nLZC/C/Dat-Cre animals cease to produce signals
that otherwise inhibit Shh expression by mesencephalic DA
neurons in the undisturbed brain (Figure 7F).
The identification of the receptor(s) on DA neurons that trans-
mit the signals that impinge on the regulation of Shh expression
can inform on the nature of the signals. We noted that the tissue
specific ablation of the canonical receptor Ret, which can bind all
members of the GDNF family of ligands, from DA neurons
utilizing the same Dat-Cre allele also employed in the present
study, resulted in alterations in dopaminergic marker gene
expression, deficits in elicited DA release and late-onset,
progressive DA neuron degeneration, (RetC/C/Dat-Cre mice)
(Kramer et al., 2007). We tested whether also the expression of
Shh is altered in the vMB of RetC/C/Dat-Cre mice. We found an
6-fold upregulation of Shh expression in RetC/C/Dat-Cre mice
compared to litter controls at 3months of age prior to observable
neurodegeneration (Figure 7F). Taken together, our studies
provide pharmacological and genetic evidence that ACh
neurons of the striatum produce signals, which engage the
canonical GDNF receptor Ret on DA neurons and repress the
expression of Shh, and regulate the expression of multiple other
genes in DA neurons.
DISCUSSION
Our results reveal that mesencephalic DA neurons express Shh
throughout life and demonstrate that DA neuron-produced Shh
is necessary for the long-term structural and functional mainte-
nance of mesencephalic DA neurons. Our studies, however,
did not uncover any evidence for an autocrine mode of Shh
signaling. Instead, we demonstrate that DA neuron-produced
Shh regulates the availability of the dopaminotrophic factor
GDNF and cholinergic physiology within the striatum in two
distinct ways: First, DA neuron-produced Shh is required for
the structural and functional maintenance of FS and ACh inter-
neurons of the striatum, which are prominent sources of GDNFin the adult basal ganglia. Second, signaling by DA neuron-
produced Shh results in the transcriptional repression of GDNF
and the regulation of expression of muscarinic autoreceptor
signaling components. Taken together, our results reveal a
means by which mesencephalic DA neurons communicate
with a subset of their striatal neuronal targets and regulate the
cellular and neurochemical homeostasis in the mesostriatal
circuit in the adult brain. We further provide in vivo evidence
that signals engaging the canonical GDNF receptor Ret ex-
pressed specifically on DA neurons and originating from the
striatum inhibit the transcription of Shh in DA neurons. Our find-
ings are consistent with the existence of a reciprocal trophic
factor signaling loop between DA neurons on one side and
ACh and FS neurons on the other side and reveal that the regu-
lation of expression of these factors has rheostat properties.
Reciprocal Trophic Factor Signaling between
Mesencephalic DA, Striatal ACh, and FS Neurons
To resolve the mechanism of action of Shh signaling in the mes-
ostriatal circuit required us to reconcile two sets of seemingly
contradictory observations: (1) the apparent cell autonomous
activity of Shh on DA neurons in the absence of evidence for
autocrine signaling, and (2) the reciprocal inhibition of expression
of Shh and GDNF in the mesostriatal circuit despite the finding
that these factors are necessary for the trophic support of ACh
and FS neurons, and DA neurons, respectively.
The inefficiency of Cre-mediated recombination of the Shh
allele resulted in Shh+ and Shh DA neurons, which allowed us
to investigate whether Shh expression by DA neurons confers
a cell survival advantage. Our results reveal a 2-fold enrich-
ment of Shh-expressing DA neurons during phenotype progres-
sion in Shh-nLZC/C/Dat-Cre mice, demonstrating that mostly
Shh/ DA neurons degenerate. Thus, our studies provide
evidence for a neuroprotective function of DA neuron-expressed
Shh on DA neurons in the adult mesencephalon and are consis-
tent with findings that exogenously supplied Shh to the basal
ganglia increases the resilience of mesencephalic DA neurons
to neurotoxic insults (Dass et al., 2005; Tsuboi and Shults,
2002). Yet, it is unlikely that the degeneration of DA neurons in
the absence of Shh expression by DA neurons results from the
interruption of a cell autonomous effect of Shh because: (1) we
cannot find evidence for the expression of the Shh coreceptors
Ptc1 or Ptc2 on mesencephalic DA neurons, and (2) the Dat-
Cremediated tissue restricted ablation of the obligate necessary
Shh signaling component Smo from DA neurons does not phe-
nocopy the Dat-Cre mediated tissue restricted ablation of Shh
from DA neurons. Instead, we find that DA neuron-produced
Shh modulates gene expression, physiology, and survival of
striatal ACh and FS neurons, which, in turn, express the dopami-
notrophic factor GDNF (Figure 8A) (Hidalgo-Figueroa et al.,
2012). Thus, themost parsimonious explanation for the apparent
cell autonomous protection of DA neurons by Shh expression is
the possibility that individual cartridges of mesostriatal circuits
act as autonomic units. In this scenario, neuronal circuits in
which DA neurons have escaped Cre-mediated recombination
of the Shh alleles will continue to supply Shh to support ACh
and FS neurons, and those ACh and FS neurons will continue
to supply GDNF to support DA neuron survival. This model isNeuron 75, 306–319, July 26, 2012 ª2012 Elsevier Inc. 315
Figure 8. Shh Signaling from Dopaminergic
Neurons Controls Structural and Neuro-
chemical Homeostasis in the Mesostriatal
Circuit
(A) Shh and GDNF provide additional means of
communication between DA, ACh, and FS
neurons of the mesostriatal circuit.
(B) Rheostat properties of trophic factor signaling.
(C) Potential signaling pathways by which Shh
originating from mesencephalic DA neurons
determines the set-point of extracellular ACh tone
in the striatum. (Red arrows indicate direction of
change observed in Shh-nLZC/C/Dat-Cre mice.)
(D) Absence of Shh signaling from DA neurons
causes progressive structural and functional
decay of the mesostriatal circuit.
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Shh Signaling in the Mesostriatal Circuitsupported by the quantification of synaptic connectivity in the
striatal microcircuit: although ACh, FS, and DA neurons elabo-
rate widespread arborizations, each neuron only contributes to
a few hundred of the estimated two million mesostriatal circuits
in the striatum (Bolam et al., 2006). Further support of a confine-
ment of Shh action to the vicinity of Shh release sites comes from
Loulier et al. (2005) who found strong expression in the adult
striatum of the Hedgehog-interacting protein (Hhip), which
inhibits Shh signaling by binding to secreted Shh, likely further
limiting the poor diffusion of Shh once secreted (Ulloa and Bris-
coe, 2007). Thus, a given DA neuron might be able to signal via
Shh to only a few ACh and FS neurons and receive trophic
support from the same neurons resulting in the appearance of
cell autonomy.
Trophic support of ACh and FS neurons by DA neuron-
produced Shh on one side and of DA neurons by ACh and FS
neuron produced GDNF on the other side could be provided in
a static manner or be induced in response to physiological
needs. We observe transcriptional activation of Shh loci in
the vMB upon (1) injection of the dopaminergic neurotoxin
6-OHDA into the mFB, (2) induction of cholinergic dysfunction
by injection of the cholinotoxin AF64a into the striatum, (3)
genetic ablation of the canonical GDNF receptor Ret from DA
neurons, and (4) genetic reduction of Shh signaling from DA316 Neuron 75, 306–319, July 26, 2012 ª2012 Elsevier Inc.neurons to the striatum. Conversely, we
find that the interruption of mesostriatal
communication by the neurotoxin 6-
OHDA or striatal injection of the Shh
antagonist cyclopamine leads to an upre-
gulation of GDNF expression in the stria-
tum, whereas striatal injection of the Shh
agonist SAG or the pharmacological in-
duced upregulation of endogenous Shh
signaling specifically frommesencephalic
DA neurons results in the inhibition of
GDNF expression in the striatum. Thus,
ACh neurons, which are trophically
dependent on Shh from DA neurons, are
a source of graded inhibitory signals for
the transcription of Shh by DA neurons.
In a mirror arrangement, DA neuronsthat are supported by GDNF modulate the expression of GDNF
in the striatum by graded Shh expression (Figure 8B).
Although our data strongly implicates striatal GDNF in the
regulation of Shh in DA neurons, our results do not exclude the
possibility that other members of the GDNF family of ligands,
all of which can signal via Ret and Gfra1, could contribute to
the modulation of Shh expression in DA neurons.
The extent of relief of transcriptional inhibition of Shh expres-
sion by signals from ACh neurons is correlated with the degree
of cholinergic dysfunction when averaged across DA neurons
and has a dynamic range of 2- to 10-fold. This observation
fits well with the established concentration-dependence and
dynamic range of Shh signaling (Ulloa and Briscoe, 2007).
Low levels of Shh signaling are necessary for tissue mainte-
nance in the developing spinal cord. At higher concentrations
Shh regulates in a concentration-dependent manner, gene
expression mediated by either transcriptional repressor or acti-
vator forms of the Shh signaling components Gli-1, -2, and -3.
At these expression levels, 1.8-fold alterations in the concentra-
tion of Shh results in distinct patterns of gene expression (Ulloa
and Briscoe, 2007), suggesting that the dynamic range of 2- to
10-fold observed in our studies could result in several distinct
physiological responses of ACh and FS neurons to Shh
signaling.
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tion of trophic factor expression must result in tight homeostatic
control of Shh and GDNF expression and links the extent of
Shh and GDNF signaling to the cell physiological status of DA,
ACh, and FS neurons. We thus propose that attenuation of
gene expression in response to physiological stress in DA,
ACh, and FS neurons will result in a corresponding reduction in
the repression of either Shh or GDNF, respectively, in such a
way that cells in need will receive increased trophic factor
support. After regaining intracellular homeostasis, reactivated
gene expression will increase trophic factor production in those
cells that had suffered from a cell physiological insult, and, in
turn, will lead to a reduction in the expression of the correspond-
ing trophic factor (Figure 8B).
These results also imply that trophic factor expression cannot
be maintained chronically at levels that are beneficial for the
survival of DA, ACh, and FS neurons once in distress. This
reasoning points to multiple functions of GDNF and Shh
signaling in the basal ganglia. Indeed GDNF signaling can regu-
late the quantal size of DA release of DA neurons (Pothos et al.,
1998). Our studies reveal a corresponding function of Shh sig-
naling on cholinergic neurotransmission extending the symmetry
of Shh and GDNF signaling from trophic interactions to neuro-
modulation within the nigro-striatal circuit.
Regulation of the Balance of Cholinergic and
Dopaminergic Tone in the Striatum by Shh Signaling
Extracellular ACh tone in the striatum is variably regulated by DA
neuron activity (Threlfell et al., 2010). However, dopaminergic
activity does not exert its effects on ACh neurons exclusively
through DA receptor signaling, but also through the regulation
of the coupling of muscarinic autoreceptors to K+ and Ca2+
channels by altering the expression of ‘‘regulator of G-protein
signaling’’ factors (RGS) (Ding et al., 2006). These findings raise
the possibility that other signaling molecules other than dopa-
mine produced by DA neurons are involved.
Our experiments show that Shh signaling originating from DA
neurons impinges onto the regulation of the set-point of ACh in
the striatum through the transcriptional regulation of M2 and
possibly by engaging a pathway that involves the Shh-depen-
dent inhibition of protein kinase A (PKA) (Ogden et al., 2008)
which is an activator of RGS4 (Huang et al., 2007), whose inhibi-
tion increases the efficacy of muscarinic autoreceptor function
(Ding et al., 2006) (Figure 8C).
Lowered cholinergic tone, a reduction of striatal GDNF levels
due to progressive degeneration of ACh neurons, and a lack of
functional adaptations by surviving ACh neurons should all
influence the physiology of surviving DA neurons in Shh-
nLZC/C/Dat-Cre mice. Consistent with this expectation, we
observe highly dynamic distortions in DA tissue content in
both the vMB and the striatum. Hence, our results suggest
that surviving DA neurons, but not surviving ACh neuron, are
able to adapt their physiology dynamically in the face of pro-
gressive neurodegeneration and decreased ACh and GDNF/
Ret signaling during early adulthood. However, by 10 months
of age, we find the manifestation of discrete locomotion and
gait disturbances, indicating that the progressive deterioration
of the mesostriatal circuit surpasses the compensatorycapacity of DA neurons in aged Shh-nLZC/C/Dat-Cre mice
(Figure 8D).
Possible Implications for Understanding the Etiology
of Diseases of the Basal Ganglia
Archetypes of basal ganglia models imply that an imbalance of
cholinergic and dopaminergic signaling in the striatum is respon-
sible for the hyper- and hypokinetic manifestations of progres-
sive movement disorders such as PD (Obeso et al., 2010). Our
work describes a mouse paradigm that recapitulates many of
the key features of the progressive cellular, neurochemical,
and functional pathologies observed in PD with apparent face-,
construct-, and predictive-validity since the functional pheno-
type that is associated with progressive neuronal loss can be
ameliorated with DA supplementation or amuscarinic antagonist
also used in the management of PD. Yet, the resemblance of the
phenotype of Shh-nLZC/C/Dat-Cremicewith PD does not extend
to the absolute direction of alterations in cholinergic tone.
In PD, ACh tone is increased (Wooten, 1990), while in our para-
digmACh tone is decreased in the absence of Shh signaling from
DA neurons, which also must occur in PD. How can these find-
ings be reconciled? Our data points to the possibility that Shh
production is increased in still functioning DA neurons in
response to the mounting pathophysiological cell stress in the
basal ganglia of PD patients. This notion is supported by several
in vivo experiments described herein: we demonstrate that the
transcription of Shh in DA neurons is strongly upregulated
upon (1) injection of 6-OHDA into the mFB, (2) induction of
cholinergic dysfunction in the striatum, (3) induction of cholin-
ergic dysfunction in the PPTg, and (4) the genetic ablation of
part of the Shh locus which abrogates the production of func-
tional Shh by DA neurons. Hence, our data are consistent with
a scenario in which prior to reaching an advanced stage of PD,
surviving DA neurons express elevated levels of Shh, which, in
turn, cause an increase of ACh tone in the striatum mediated
by a downregulation of muscarinic autoreceptor efficacy.
Our data suggest that the pharmacological manipulation of
Shh signaling can be used to modulate cholinergic tone and
reinforce the rationale for supporting growth factor signaling as
a disease modifying therapeutic strategy in basal ganglia
diseases. However, the uncovered negative feedback regulation
of endogenous growth factor expression within the mesostriatal
circuit predicts that exogenously supplied trophic factors could
inhibit endogenous expression of the same factors possibly cur-
tailing the therapeutic benefit of this approach. Instead, our
results point to the possibility that undercutting the negative
feedback regulation of endogenous growth factor expression
could result in therapeutically effective increases of trophic
factor signaling within the basal ganglia.
EXPERIMENTAL PROCEDURES
Mouse Strains
The Shh-nLZC allele was generated by homologous recombination in
ES cells. Additional construction details, mouse strains and genotyping proce-
dures are described in Supplemental Experimental Procedures. All animal
handling and procedures were approved by the Animal Care and Use
Committee of Columbia University and performed in accordance with NIH
guidelines.Neuron 75, 306–319, July 26, 2012 ª2012 Elsevier Inc. 317
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Shh Signaling in the Mesostriatal CircuitImmunohistochemistry
Immunohistochemistry was performed on 16–100 mm cryostat-cut sections
using primary and secondary antibodies listed in Supplemental Experimental
Procedures. Images were acquired on a Zeiss LSM510 Meta confocal micro-
scopes. Quantification of the size of populations of cells was estimated by
the optical fractionator method described in Supplemental Experimental
Procedures.
Quantification of GDNF Tissue Content
Tissue levels of GDNF were measured by ELISA (GDNF Emax ImmunoAssay
System; Promega, Madison, WI), according to the manufacturer’s protocol.
Quantification of Gene Expression
Total RNA from striatum and lateral vMB containing the entire SN and VTA was
isolated (RNeasy Mini Kit; QIAGEN) and reverse transcribed using oligo(dT)
primers and the SuperScript First-Strand Synthesis System (Invitrogen),
according to the manufacturers’ protocols. Relative changes in gene expres-
sion were quantified by rtPCR using TaqMan gene expression assays (Applied
Biosystems) with amplicons listed in Table S2 and calculated by the DDCt
method.
Neurochemical Analysis
Determination of the concentration of dopamine and acetylcholine and
neurotoxicological challenges were performed as described in Supplemental
Experimental Procedures.
Locomotion Analysis
Analysis of gait parameters by forced locomotion was performed by ventral
plane videography (Digigait, Mouse Specifics, Inc., Boston, MA) Spontaneous
motor activity wasmeasured in an open field arena using automatic tracking at
6 Hz by an EthoVision 3.1 system (Noldus Information Technology, Leesburg,
VA). Derivation of indices for turning bias is described in Supplemental Exper-
imental Procedures.
Statistical Analysis
The mean and SEM of values were calculated and the significance of all pair-
wise comparisons was determined by two-tailed distribution homoscedastic
Student’s t test and by ANOVA, including a repeated-measures factor when
necessary. Follow up analysis between groups with multiple comparisons
was by Tukey’s post hoc test. Nonparametric data were analyzed by Mann-
Whitney U test. For all box plots, the box includes data points between the
25th and 75th percentile of all values, with the line representing the median
value. The lines and whiskers represent data between the ninth and ninety-first
percentile and individual dots represent outlier points.
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, two tables, and Supplemental
Experimental Procedures and can be found with this article online at http://
dx.doi.org/10.1016/j.neuron.2012.05.018.
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